Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | IM |
The patient received only one dose of RabAvert vaccine, the second dose was delayed due to lack of insurance coverage; Case reference number US-BN-2024-002827 is a spontaneous case initially received from a pharmacist via Med Communication (reference number: USBAV24-3171) on 02-Dec-2024 and concerns a 78-year-old female patient. The patient's current medical condition included diabetes mellitus, thyroid issues, hypertension and hyperlipidemia. The patient's concomitant medication details were not provided. On unspecified date, patient experienced dog exposure. On 27-Nov-2024, the patient received the first dose of RabAvert vaccine (batch number: unknown), at unknown dose, intramuscularly, at unknown site of administration, for post exposure. The patient only had one dose of RabAvert, the second one was delayed due to lack of insurance coverage (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A 78-year-old female patient received the first dose of RabAvert vaccine, at unknown dose, intramuscularly, at unknown site of administration, for post exposure. The patient only had one dose of RabAvert, since the second one was delayed due to lack of insurance coverage which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's current medical condition included diabetes mellitus, thyroid issues, hypertension and hyperlipidemia while concomitant medication details were not provided. Inappropriate schedule of product administration is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 78-year-old female patient received the first dose of RabAvert vaccine, at unknown dose, intramuscularly, at unknown site of administration, for post exposure. The patient only had one dose of RabAvert, since the second one was delayed due to lack of insurance coverage which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's current medical condition included diabetes mellitus, thyroid issues, hypertension and hyperlipidemia while concomitant medication details were not provided. Inappropriate schedule of product administration is assessed as not related to suspect product but to human factor. The case is non-serious.
Diabetes mellitus; Hyperlipidemia; Hypertension; Thyroid disorder